Since intravitreal injection of anti-VEGF drugs is the gold standard for therapies of eye diseases, such as wet AMD, DME, and DR, biosimilars for successful anti-VEGF drugs (ranibizumab, bevacizumab, and aflibercept) have been developed and tested in clinical trials [135,136]. Here, VEGFA is linked to eye disorder.